Aminoglycosides inhibit translation in bacteria by binding to the A site in the ribosome. Here, it is shown that, in yeast, aminoglycosides can also interfere with other processes of translation in vitro. Steady-state aminoacylation kinetics of unmodi®ed yeast tRNA Asp transcript indicate that the complex between tRNA Asp and tobramycin is a competitive inhibitor of the aspartylation reaction with an inhibition constant (K I ) of 36 nM. Addition of an excess of heterologous tRNAs did not reverse the charging of tRNA Asp , indicating a speci®c inhibition of the aspartylation reaction. Although magnesium ions compete with the inhibitory effect, the formation of the aspartate adenylate in the ATP±PP i exchange reaction by aspartyltRNA synthetase in the absence of the tRNA is not inhibited. Ultraviolet absorbance melting experiments indicate that tobramycin interacts with and destabilizes the native L-shaped tertiary structure of tRNA Asp . Fluorescence anisotropy using¯uorescein-labelled tobramycin reveals a stoichiometry of one molecule bound to tRNA Asp with a K D of 267 nM. The results indicate that aminoglycosides are biologically effective when their binding induces a shift in a conformational equilibrium of the RNA.
Introduction
Aminoacylation of transfer RNA (tRNA) is essential for cell replication and growth. It is therefore an attractive target for therapeutic intervention. The following strategies have been explored so far: (i) amino acid analogues (Loft®eld, 1973; Vasquez, 1974) , (ii) oligonucleotides mimicking tRNA features (Loft®eld, 1973) , (iii) aminoacyl-adenylate analogues (Sassanfar et al., 1996) and (iv) blocking the formation of initiator tRNA fMet (Loft®eld, 1973) . Up to now, most of the known natural products targeted against speci®c aminoacyl-tRNA synthetases (aaRSs), or apparent amino acid speci®cities of the aaRSs could not be developed into an antibiotic due mainly to their lack of systemic bioavailability (Schimmel et al., 1998) . The correct aminoacylation of tRNAs by their cognate synthetase is crucial for the accurate transmission of genetic information. It is determined by speci®c structural features of the tRNAs (Giege Â et al., 1998) . Although the global architecture of tRNAs is highly conserved, subtle protein±tRNA interfacial contacts guarantee speci®c aminoacylation of each tRNA by a speci®c synthetase. The aminoacylation reaction of yeast tRNA Asp ( Figure 1A ) by its cognate aspartyl-tRNA synthetase (AspRS) is biochemically (Romby et al., 1985; Pu Ètz et al., 1991; Frugier et al., 1994) and structurally well described Cavarelli et al., 1993) .
Aminoglycosides are known to interact with ribosomal RNAs inhibiting translation at the ribosome level (Blanchard et al., 1998) . They further interfere with translational control (Tok et al., 1999) , viral transcription of HIV (Zapp et al., 1993; Mei et al., 1995) and ribozyme activity (reviewed in Schroeder et al., 2000) . Here, the interaction of tobramycin, a common aminoglycoside of the 2¢deoxystreptamine group ( Figure 1B) , with the yeast tRNA Asp ±AspRS complex was investigated. It is demonstrated that the aminoacylation of tRNA Asp , a primary step in protein synthesis, can be speci®cally inhibited by tobramycin with binding af®nities in the nanomolar range. Tobramycin is not the ®rst compound shown to inhibit aminoacylation. Purpuromycin had already been shown to inhibit the aminoacylation reaction at the level of tRNA charging, but with several molecules of purpuromycin binding with micromolar af®nity to all tRNAs (Kirillov et al., 1997) . Similarly, tobramycin is not the ®rst compound shown to interfere with an RNA±protein enzymic system. Recently, it has been shown that synthetic benzimidazole derivatives inhibit the processing of the precursor-tRNAs to mature tRNAs by the RNA subunit of Escherichia coli RNase P (M1 RNA), but with I 50 values between 5 and 20 mM (Hori et al., 2001) .
Results
Aspartylation activity of tRNA Asp in the presence of tobramycin Aminoacylation experiments with yeast AspRS (Figure 1 ) reported here were carried out on molecules obtained in vitro by transcription with T7 RNA polymerase. Figure 2 compares the aspartylation kinetics of wild-type tRNA Asp transcript in the absence and presence of the aminoglycoside tobramycin. The aspartylation of tRNA Asp decreases with increased concentrations of tobramycin (1±3 mM). The lines in the absence and presence of the antibiotic intercept the y-axis at one point, indicating that tobramycin acts as a competitive inhibitor with respect to tRNA Asp (Figure 2 ). The Michaelis±Menten parameters k cat and K m in the presence and the absence of tobramycin and/or total tRNA from yeast are summarized in Table I together with the relative kinetic speci®city constants (k cat /K m ) rel = (k cat / K m ) tobramycin /(k cat /K m ) ±tobramycin . A more intuitive number is also included, namely the loss in aminoacylation ef®ciency caused by the antibiotic. The presence of Binding of tobramycin leads to conformational changes in yeast tRNA Asp and inhibition of aminoacylation The EMBO Journal Vol. 21 No. 4 pp. 760±768, 2002 tobramycin affects mainly the K m by factors up to 30-fold (for 3 mM tobramycin at an ATP:Mg 2+ ratio of 5:15 mM), while the k cat is only decreased 2-fold. As a consequence the relative speci®city constants are decreased and the loss in aminoacylation ef®ciency increases up to 60-fold. Further, aminoacylation experiments using fully modi®ed yeast tRNA Asp reveal that tobramycin inhibits charging to the same extent, showing equivalent kinetic parameters for aminoacylation compared with those of the corresponding in vitro transcripts (data not shown). The addition of tobramycin at various times or directly before the start of the reaction by AspRS does not show a change in the aminoacylation kinetics (data not shown). Tobramycin does not exhibit a time dependence of the inhibition of the aminoacylation reaction of tRNA Asp . Thus, the kinetics measurements indicate that binding of tobramycin leads to spatial conformational changes of the tRNA, resulting in a reduced af®nity of tRNA Asp for AspRS or a loss in transition state stabilization of the tRNA Asp ±AspRS complex.
To determine whether the inhibition is speci®c for the tRNA Asp ±AspRS interaction, the effect of tobramycin on tRNA Asp was determined in the presence of an increasing excess of competitor tRNA. For this purpose tRNA Asp is incubated together with up to 2-fold excess of tRNA Phe over tobramycin. No recovery of the aminoacylation activity is observed after the addition of native tRNA Phe ( Figure 3A ). In the high concentration range of competitor tRNA an inhibition effect of the aminoacylation reaction is noticeable, probably due to the addition of high concentrations of charges and salt. Moreover, assays in the presence of high levels of total tRNA (3-to 50-fold excess over tobramycin) also resulted in no recovery of aspartylation activity (Table I) . Further analysis of the kinetic parameters shows only small effects on the aspartylation reaction. A loss of speci®city by a factor of 8 is observed, but remains essentially unchanged with increasing concentrations of total tRNA.
The next question addressed was whether tobramycin can speci®cally inhibit tRNA Asp charging within a mixture of various tRNA families. The level of aspartylation and phenylalanylation within a fraction of total tRNAs was monitored in the absence and presence of tobramycin. Figure 3B reveals that tobramycin exhibits the same inhibition potential towards the aspartate system as shown (Gangloff et al., 1971) showing the change of the ®rst base pair (U 1 ±A 72 ®G 1 ±C 72 ); nucleotides are numbered according to Sprinzl et al. (1998) . Identity nucleotides of the aspartylation reaction are shadowed (Pu Ètz et al., 1991; Frugier et al., 1994) . The G 1 ±C 72 wild-type transcript shows equivalent aspartylation parameters to those of fully modi®ed tRNA Asp and U 1 ±A 72 transcripts (Pu Ètz et al., 1991) . (B) Structure of the aminoglycoside antibiotic tobramycin, a member of the 2¢deoxystreptamine group. The antibiotics of the aminoglycoside family result from modi®cations of neamine, a two-ring system made of 2-deoxystreptamine (called ring B or II) glycosylated at the 4-position by a 6-membered amino-sugar (called ring A or I) of the glycopyranoside series. Further modi®cations with various amino-sugars at the 6-position lead to the kanamycin family.
Inhibition of tRNA aminoacylation for puri®ed tRNA Asp (see Figure 2) . The aspartylation reaction is inhibited by~20%. However, the phenylalanylation of tRNA Phe within the same pool is not affected ( Figure 3B ).
Electrostatic interactions play a dominant role in aminoglycoside±RNA binding (Tor et al., 1998) . If the positively charged aminoglycoside is in competition with divalent metal ions, inhibition of the tRNA charging reaction could be overcome by increased concentrations. In one series of experiments, the ATP:MgCl 2 ratio was kept constant (1:3), while varying the magnesium ion concentration from 7 to 60 mM. Figure 4 illustrates that the aminoacylation reaction reaches its maximum at 10 mM MgCl 2 . In the presence of tobramycin this maximum is reduced and shifted to 15 mM MgCl 2 . Reaction mixtures containing >12 mM MgCl 2 reveal a decrease in aminoacylation activity as well as a reduction in the inhibition effect caused by tobramycin. A second set of experiments was carried out under constant ATP conditions (5 mM) with increased MgCl 2 concentrations ranging from 1 to 50 mM giving identical results (data not shown).
Tobramycin could bind speci®cally to the catalytic site of yeast AspRS as a structural analogue of ATP. To exclude this possibility, the concentration of ATP in the aspartylation reaction was reduced from 5 to 2 mM ATP (leading to a change in the ATP:MgCl 2 ratio from 1:3 to 1:5). The effect of tobramycin on the aspartylation kinetics of tRNA Asp is compared before and after the change of the ATP:MgCl 2 ratio ( Figure 5A and Table I ). A slight change in the initial velocity is observed in the absence of the antibiotic. However, in the presence of tobramycin the inhibitory effect is identical, showing that ATP is not competing with tobramycin for binding to the catalytic site of AspRS.
Aspartyl-adenylate formation by ApsRS is not inhibited by tobramycin
During the ®rst step in the aminoacylation reaction, AspRS forms the activated aspartyl-adenylate in the absence of tRNA Asp . A series of pyrophosphate exchange [PP i ] experiments were designed to estimate the degree of inhibition during adenylate formation. AspRS was incubated with radioactively labelled pyrophosphate and aspartic acid in the presence and the absence of the aminoglycoside. The initial rate of the pyrophosphate exchange reaction at all three concentrations of tobra- mycin (0.3±30 mM) tested is at the same level and no difference at the level of pyrophosphate incorporation either in the absence or presence of the aminoglycoside is visible ( Figure 5B ). Therefore, tobramycin does not act as a structural analogue of ATP or an amino acid in the aminoacylation reaction and does not interact with the catalytic domain of the AspRS itself during the amino acid activation step.
Ultraviolet absorbance melting experiments reveal a destabilization of the tertiary structure of tRNA Asp upon interaction with tobramycin Ultraviolet (UV) absorbance melting curves were performed to assess the effect of the tobramycin±tRNA Asp interaction on the overall structural stability of the tRNA Asp . In the presence of 3 mM MgCl 2 the shape of the melting curve of tRNA Asp shows a sharp and symmetrical pro®le ( Figure 6 ) indicating a highly cooperative melting transition in a quasi all-or-none manner. The calculated melting temperature (T m ) of 65°C and the shape of the transition is in agreement with published data (Puglisi et al., 1993) . After the addition of 1 mM tobramycin the melting pro®le of tRNA Asp changes dramatically with a drop of the T m of 10°C to 55°C. The T m and the shape of the melting transition in the presence of the antibiotic resemble that of tRNA Asp in the absence of magnesium ions (Puglisi et al., 1993) . This broad, noncooperative transition indicates several melting domains related to the independent melting behaviour of the helical regions of the tRNA. Therefore, it appears that tobramycin destabilizes the functional tertiary conformation of the tRNA Asp and/or the tRNA Asp ±AspRS complex including magnesium ions and the adenylate. Indeed, disruption of tertiary interactions in the core of tRNA Asp results in a decrease of (k cat /K m ) rel (Puglisi et al., 1993) .
Fluorescence anisotropy experiments
In order to determine quantitatively the speci®city and stoichiometry of ligand binding, the¯uorescence anisotropy of¯uorescein-labelled tobramycin (Tob±Fl) was measured. Figure 8 shows the change in¯uorescence anisotropy as a function of tRNA concentration. Figure 7B ) containing the identity elements for aspartylation, but with a disrupted 3D structure, was also titrated. The initial value of thē uorescence anisotropy of Tob±Fl does not change signi®cantly with the addition of tRNA Asp mutant D. The inset in Figure 8 shows the titration of Tob±Fl with fully modi®ed tRNA Phe . The plot displays a large and slightly sigmoidal increase in the¯uorescence anisotropy tõ (105 T 0.08) Q 10 ±3 at very high concentrations of tRNA Phe . Upon binding to tRNA Phe the¯uorescence anisotropy is reduced dramatically, indicating that thē uorophore is constrained in some manner upon binding to the RNA. The af®nity of Tob±Fl for tRNA Phe is much . In this case, tobramycin binds to the RNA deep groove centred about a stem±loop junction site. A portion of the bound tobramycin, ring III and partly II ( Figure 1B) , is encapsulated between the¯oor of the deep groove and a looped-out cytosine residue that forms a¯ap over the binding site in the complex with the aptamer (Jiang et al., 1997) . The primary amino group is the site of attachment to the column in the SELEX experiment of the tobramycin aptamer and also the site of labelling with the¯uorescein dye in our experiments. This amino group on the ring system I reaches slightly out into the solution (Jiang et al., 1997) . The moderate change in the anisotropy value in the case of the aptamer can be explained by its degree of freedom. The relatively low anisotropy of Tob±Fl bound to tRNA Asp indicates that thē uorescein is still very mobile. The¯uorescein group attached to the tobramycin probably reaches out into the solution, while other amino groups of tobramycin seem to be responsible for the speci®c binding at the site of the tertiary interaction, possibly between the D and T domains. However, the high anisotropy value found for Tob±Fl bound to tRNA Phe indicates that the reporter dye must be immobilized to a high degree.
The yeast AspRS enzyme is known to aminoacylate both the yeast tRNA Asp and the tRNA Asp from E.coli. In contrast, the bacterial enzyme of AspRS binds both tRNAs with similar af®nity but cannot charge yeast tRNA Asp . A crystal structure of an inactive complex between yeast tRNA Asp and E.coli AspRS has recently been published con®rming the crucial role of the native and properly adapted tRNA three-dimensional structure (Moulinier et al., 2001) . The sequence of yeast tRNA Asp differs from E.coli tRNA Asp in 35 positions, four of which are located in the D domain and six in the T domain with two positions located in the T loop directly. The¯uorescence anisotropy binding assay is used to test for binding of Tob±Fl to E.coli tRNA Asp . In contrast to yeast tRNA Asp , the addition of E.coli tRNA Asp does not induce a signi®-cant increase in the initial value of the¯uorescence anisotropy of Tob±Fl (Figure 8 ). This corresponds to the behaviour of the aminoacylation-inactive tRNA Asp mutant D (Figure 8 ) containing the identity elements for aspartylation, but with a disrupted 3D structure. Since Tob±Fl does not bind to E.coli tRNA Asp , inhibition of aminoacylation of yeast AspRS by tobramycin is not expected. This experiment demonstrates that the conformational change necessary for tobramycin binding to a tRNA depends on those parts of the tRNA sequence underlying the tertiary structure.
To investigate further the effect induced by tobramycin binding to the tRNA Asp on its interaction with AspRS, tRNA Asp was labelled at the free 5¢ terminus with thē uorescent dye erythrosin (tRNA Asp -Ery). The¯uores-cence anisotropy value of tRNA Asp -Ery is very high (38 T 0.2 Q 10 ±3 ) in the absence of AspRS (Figure 9 ). The¯uorescent dye might be restricted in its rotational freedom due to some interaction with the single-stranded 3¢ CCA terminus. Upon addition of AspRS the¯uores-cence anisotropy value dropped down to a minimum of (28 T 0.16) Q 10 ±3 at 100 nM AspRS. Upon complex formation between tRNA Asp and AspRS a conformational rearrangement occurs that allows the¯uorescent dye more rotational freedom. At the end of the titration with AspRS the inhibitor molecule was added in three steps to the tRNA Asp ±AspRS complex. The¯uorescence anisotropy value increased back to its original value with increasing concentrations of tobramycin. If tobramycin is bound to tRNA Asp , AspRS can no longer bind to the tRNA and the¯u orescent dye can fold back at its original position. When tobramycin was allowed to form a complex with tRNA Asp before titration with AspRS, no signi®cant change in thē uorescence anisotropy value was observed during the whole titrational range. Thus, the tobramycin±tRNA Asp complex functions as a competitive inhibitor in the aminoacylation reaction by preventing the synthetase from binding to its substrate.
The set of¯uorescence anisotropy measurements shows that the inhibitor acts by binding to the tRNA substrate of the enzymic reaction thereby forming an inhibitory complex.
Aminoacylation kinetics were performed under oversaturating inhibitor concentrations. Under these conditions and a measured K D in the lower nanomolar range one can assume that the concentration of the inhibitory complex is equal to the concentration of the substrate, e.g. tRNA Asp . A detailed analysis shows that the inhibition constant K I using the standard relationship (Equation 4):
with I tRNA Asp Â Tob is in the lower nanomolar range at 36 nM. If one assumes that tobramycin acts as an inhibitor directly on the Inhibition of tRNA aminoacylation enzyme, the calculated K I would increase into the upper micromolar range (125 mM), a value much higher than the measured af®nity binding constant.
Discussion
Our steady-state kinetics of the aminoacylation reaction demonstrate that tobramycin speci®cally inhibits by a competitive mechanism the charging of tRNA Asp in vitro (Figure 2 ) even in the presence of non-cognate tRNAs (either a mixture of all native tRNAs or in the presence of tRNA Phe ) (Figure 3 ). Tobramycin is in competition with magnesium ions (Figure 4 ), but not with ATP ( Figure 5A ). Tobramycin does not act at the level of the formation of activated aspartyl-adenylate by AspRS ( Figure 5B ). The dissociation constant measured by¯uorescence anisotropy is in the nanomolar range (Figure 8 ). UV absorption melting curves indicate that tobramycin disrupts the native conformation of tRNA Asp (Figure 6 ). Tobramycin does not bind either to a mutated tRNA Asp , which does not display a tertiary structure, or to E.coli tRNA Asp with sequence variations in both the D and T domains (Figure 8) . The non-native tobramycin±tRNA Asp complex acts as a competitive inhibitor of the aspartylation reaction (Figure 9 ). Chemical and enzymic footprinting studies con®rm that the binding of tobramycin alters speci®cally the native 3D structure of yeast tRNA Asp (to be published elsewhere).
Binding of tobramycin to a tRNA does not lead automatically to a conformational change interfering with the recognition of the tRNA identity elements by the cognate aaRS. Indeed,¯uorescence anisotropy measurements show micromolar binding of tobramycin to yeast tRNA Phe (Figure 8 ), but the phenylalanylation of yeast tRNA Phe by PheRS is not inhibited by tobramycin ( Figure 3B ). Among aminoglycosides, neomycin B has been demonstrated to inhibit the phenylalanylation of E.coli tRNA Phe with an I 50 (e.g. concentration at 50% inhibition of the aminoacylation reaction) in the upper micromolar range (Mikkelsen et al., 2001) . Using a crude extract of the tRNA fraction higher concentrations of the aminoglycoside are needed for the inhibition of the aminoacylation reaction. In the yeast tRNA Phe ± aminoglycoside crystal complex only one neomycin molecule is observed. Neomycin B is bound to the upper part of the anticodon stem. The same authors tested the inhibition of lead (Pb 2+ ) cleavage of yeast tRNA Phe by various aminoglycosides. They concluded that neomycin B binds probably with two molecules to tRNA Phe with an I 50 of 300 mM. Previously, several aminoglycosides had been shown to bind to tRNA Phe at various sites, stabilizing the structure of tRNA Phe in the same manner as polyamines (Kirk and Tor, 1999) . The strongest stabilization effect was observed by UV absorbance melting experiments with a DT m of +14°C upon addition of neomycin B (10 mM).
Aminoglycosides share common structural features with polyamines and one can expect that they can bind non-speci®cally to all RNAs (Robinson and Wang, 1996) . Sequence independent binding in the deep groove of duplex RNA for both of types of cationic ligands is within the millimolar range and sensitive to both pH and salt concentrations (Jin et al., 2000) . Tobramycin binding to an RNA duplex enhances thermal stability of a poly(rI)±poly(rC) RNA duplex, decreasing with increasing sodium ion concentrations and pH. Viscometric measurements are consistent with a tobramycin-induced nonspeci®c and non-intercalative binding into the deep groove. Such considerations and the fact that aminoglycosides interact with a great variety of RNA molecules (for recent reviews see Walter et al., 1999; Schroeder et al., 2000) have led to the notion that their binding is not very speci®c.
Here, we show that an aminoglycoside antibiotic in¯uences speci®cally a protein±RNA interface leading to inhibition of function only if the binding is correlated with a conformational change. This observation, together with recent results on the 30S particle of the ribosome (Ogle et al., 2001 ) and a complex of the A site of the 16S rRNA with aminoglycosides (Vicens and Westhof, 2001) , lead us to propose a model for the differences in ef®ciency of inhibition induced by aminoglycosides in various systems. We have shown that the antibiotic binds to the tRNA substrate of the catalytic reaction and interferes with enzymic function because it induces a conformational change in the substrate ( Figure 10A ). Small molecules, AspRS is able to recognize the spatial arrangement of the identity elements on the tRNA structure and binds to the native conformation of tRNA Asp . If the functional complex is formed, the tRNA Asp becomes aspartylated by AspRS. Tobramycin also binds with high af®nity to tRNA Asp . Binding of tobramycin disrupts and destabilizes the native structure of tRNA Asp , and AspRS is unable to bind to the unfolded tRNA Asp conformation. Thus, the antibiotic, by interacting with the native tertiary structure of tRNA Asp , can interfere with the subsequent productive interaction of tRNA Asp with AspRS. (B) Conformational states of RNA molecules and interaction with ligands. In the native conformation (A) an RNA molecule can perform its natural function. Upon a conformational change, the RNA adopts either a non-native conformation or another conformation related to alternative function (B). Polyamines and speci®c divalent metal ions (e.g. magnesium ions) usually stabilize the native state of an RNA molecule. In contrast, inhibitors, antibiotics or appropriate cofactors may shift the equilibrium to either a non-native state of the RNA or an alternative conformation, thereby interfering with its function.
like magnesium ions, polyamines and related aminoglycosides, may bind non-speci®cally and stabilize the native folding of RNA molecules, leading to proper biological function. In contrast, when the binding of a small molecule or antibiotic leads to the stabilization of a non-native RNA conformation or to a shift in a conformational equilibrium, biological errors or enzyme inhibition can be promoted ( Figure 10B ).
Aminoglycosides or novel small molecular RNA binders that are speci®c for various RNA folds may constitute lead compounds for developing new and highly speci®c RNA drug targets. Despite the use of high through-put screening (HTS) methods (reviewed in Hermann and Westhof, 2000) , adequate ®lters are necessary for choosing the RNA targets.
Materials and methods

Aminoacylation experiments
Yeast AspRS was puri®ed as described elsewhere (Lorber et al., 1983) . Aminoacylation tests were performed in 0.1 M HEPES±KOH pH 7.5, 30 mM KCl, 15 mM MgCl 2 , 5 mM adenosine triphosphate, 52 ml [L-3 H]aspartic acid in the absence and presence of tobramycin at various concentrations in a 100 ml volume. These reactions were performed under steady-state conditions of enzyme (2.5 nM AspRS) and tRNA substrate concentrations (0.05±0.8 mM) and subsaturating concentrations of aspartic acid at 30°C as described (Perret et al., 1990; Pu Ètz et al., 1991) . Apparent K m and k cat values obtained at subsaturating concentrations of amino acid, were derived from a Lineweaver±Burk plot. k cat /K m values for replicate experiments varied at most by 15%.
Adenylate formation by AspRS [ 32 P]PPi±ATP exchange reactions (200 ml) were performed in 100 mM HEPES±KOH pH 7.4, 10 mM MgCl 2 , 2 mM ATP, 5 mM L-aspartate, 2 mM [ 32 P]PP i (~2 c.p.m./pmol) and 0.25 mg/ml AspRS. ATP synthesis was determined as described (Kern and Giege Â, 1979) . Values for replicate experiments varied at most by 5%.
Ultraviolet absorbance melting curves
Absorbance was monitored on a 941 Uvikon UV spectrophotometer equipped with an external waterbath at 258 nm and temperature was increased continuously at 0.5°C/min. Incubation conditions were 10 mM Na-cacodylate pH 6.5, 50 mM NaCl, 3 mM MgCl 2 in the absence and presence of tobramycin (1 mM). The data are normalized for differences in tRNA concentration and given as a (fraction of molecules in a dissociated state) (Marky and Breslauer, 1987) .
Fluorescent labelling of in vitro transcribed tRNA Asp molecules tRNA Asp transcripts were prepared by in vitro transcription (Pu Ètz et al., 1991) in the presence of [g-32 P]ATP. Transcription was started by the addition of a-sulfur-substituted guanosine monophosphate (GMP-aS) at 40°C. Additions of GMP-aS were repeated every 20 min for 2 h. Fulllength tRNA Asp transcripts were puri®ed using PAGE. tRNA Asp transcripts (20 pmol) were labelled with a 1 mM solution of the appropriate dye (erythrosin-5-iodoacetamide, Molecular Probes Europe) in 30% dimethylsulfoxide (DMSO), 50 mM dithiothreitol (DTT), 20 mM EDTA, 50 mM Tris buffer pH 8.3 at 40°C for 2 h in the dark. Labelled tRNA Asp transcripts (tRNA Asp -Ery) were puri®ed using PAGE.
Fluorescence anisotropy measurements 5-carboxy¯uorescein-labelled tobramycin was synthesized and veri®ed as described elsewhere with some modi®cations . Tobramycin (50 mg,~107 mmol) was dissolved in 500 ml H 2 O and 500 ml DMSO. Five hundred microlitres of 5-carboxy¯uorescein succimidyl ester DMSO solution (10 mg,~21 mmol) were added and stirred for 1 h at 5°C. The reaction was stopped by adding 10 ml of H 2 O. To purify the labelled product the solution was passed twice through a weakly cationic exchange column (Amberlite CG50; Sigma) equilibrated with H 2 O at pH 5.5, washed with 500 ml of H 2 O, 500 ml of 0.025 M ammonium hydroxide and eluted with 0.25 M ammonium hydroxide. The product (Tob±Fl) was further puri®ed on a C 18 -reversed phase column (PR-ODS; Beckman) using a linear gradient of triethylamine acid (TEAAC), 0.1 M, pH 6.0 and acetonitrile from 5 to 100%. The product was lyophilized and veri®ed by NMR and mass spectroscopy [FABMS: 826 (M+H); Wang et al., 1996] . The 6¢amino group of tobramycin is preferentially acetylated, since it is the only unhindered primary amino group (Tangy et al., 1983; Wang et al., 1996) . Steady-state¯uorescence anisotropy experiments were performed using an Aminco SLM 8100 uorescence spectrophotometer with two photomultiplier tubes (T set-up The¯uorescence intensity I is measured using vertical excitation and emission polarizers, and vertical and horizontal emission polarizers. G is the correction factor and the subscripts v and h refer to¯uorescence with vertical and horizontal polarizers, respectively, in the order excitation, emission. Anisotropy values were integrated over 10 s and an average of 10 measurements was used, or until a reproducible value was measured (error <0.3%). The anisotropy of¯uorescein attached to tobramycin is 25.53 Q 10 ±3 compared with 12 Q 10 ±3 for free dye in solution. Binding studies were carried out by titrating a solution of Tob±Fl with aliquots of a tRNA stock solution. Binding of Tob±Fl leads to a decrease in the rotation of the¯uorescein upon formation of the RNA±inhibitor complex measured as anisotropy. The dissociation constant was determined from anisotropy measurements using a 10 nM Tob±Fl solution in 20 mM HEPES±KOH pH 7. 
